Back to search

University of Strathclyde

Preclinical development of a treatment for systemic lupus erythematosus

Abstract

dc:description.abstract

Janus Kinase 1 (JAK1) inhibitor 1 is being developed between GlaxoSmithKline(GSK) and Galapagos for the treatment of systemic lupus erythematosus (SLE). Themedicinal chemistry route to 1 has been scaled up to provide kilogram quantities of 1for clinical trials. A new sustainable route to 1 is required to fund larger clinicalstudies and enable commercial manufacture.A new route was identified to prepare 1 using a Suzuki-Miyaura coupling in the finalsynthetic step. For the new route to be carried out in the pilot plant, it was necessaryto develop the final synthetic step to control palladium and impurity levels in orderfor 1 to be prepared in acceptable quality for clinical use. The new Suzuki-Miyauracoupling has been scaled up using an 45 Kg input of 149 preparing a total of 165 Kg1 containing <10ppm Pd and all impurities within specification.Metabolism of drug substance 1 has been investigated in order to develop 1 into amedicine. The synthesis of metabolites 157 and 167 was carried out to provideanalytical markers for a clinical study.

Degree

thesis:*
Name dc:type.qualificationname
mphil
Level dc:type.qualificationlevel
masters-pg
Grantor dc:publisher.institution
University of Strathclyde
Year dc:date.issued
2014

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Murray, Erin
Advisor dc:contributor.advisor
  • Tomkinson, Nick
Author Identifier dc:creator.authoridentifier
  • 201292536

Rights

Identifiers

dc:identifier.*
Identifier
T16082

Chain of custody

source
Harvested from
University of Strathclyde
Base URL
stax.strath.ac.uk/catalog/oai
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Murray, Erin. Preclinical development of a treatment for systemic lupus erythematosus. masters-pg thesis, University of Strathclyde, 2014. https://stax.strath.ac.uk/concern/theses/tx31qj05f